This page contains a brief description that does not cover the medication. For more information read the review in Felleskatalogen.no for the respective drug.
Otezla (apremilast) are immunomodulatory tablets, a so-called PDE4 (phosphodiesterase inhibitor).
Otezla is used against Psoriasis (plaque psoriasis) and Psoriatic arthritis. The drug has also shown an effect against Behcet's disease (on mucosal ulcers). and Rheumatoid arthritis. It has been tested by Rheumatoid arthritis and Ankylosing spondylitis, but did not show safe effect (references: Genovese MC, 2015, RheumNow)
Otezla should not be used during pregnancy
- The most common dose is 30 mg morning and evening
- At startup, the following regimen is used: Day 1: 10 mg tomorrow. Day 2: 10 mg tomorrow, 10 mg evening. Day 3: 10 mg tomorrow, 20 mg evening. Day 4: 20 mg tomorrow, 20 mg evening. Day 5: 20 mg tomorrow, 30 mg evening. Day 6 and beyond: 30 mg tomorrow, 30 mg evening
- H-prescription which is covered by the patient's health trust
- UpToDate (American side)
- The Norwegian “Common Catalog” (Patient Edition)
- The Norwegian "Common Catalog"